Current treatment of IgA nephropathy
IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia and the
Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and …
Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and …
IgA nephropathy
Abstract Globally, IgA nephropathy (IgAN) is the most common primary glomerulonephritis
that can progress to renal failure. The exact pathogenesis of IgAN is not well defined, but …
that can progress to renal failure. The exact pathogenesis of IgAN is not well defined, but …
[HTML][HTML] An update on the pathogenesis and treatment of IgA nephropathy
JK Boyd, CK Cheung, K Molyneux, J Feehally… - Kidney international, 2012 - Elsevier
Over the past two decades significant progress has been made in unravelling the complex
pathogenesis of immunoglobulin A nephropathy (IgAN). Excess amounts of poorly …
pathogenesis of immunoglobulin A nephropathy (IgAN). Excess amounts of poorly …
[HTML][HTML] Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies
Infections have been considered to play a critical role in the pathogenesis of IgA
nephropathy (IgAN) because synpharyngitic hematuria is a common feature in IgAN …
nephropathy (IgAN) because synpharyngitic hematuria is a common feature in IgAN …
Angiotensin II blockade and renal protection
H Kobori, H Mori, T Masaki… - Current pharmaceutical …, 2013 - ingentaconnect.com
Current national guidelines have recommended the use of renin-angiotensin system
inhibitors, including angiotensin II type 1 receptor blockers (ARBs), in preference to other …
inhibitors, including angiotensin II type 1 receptor blockers (ARBs), in preference to other …
Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options
The concept of renoprotection has evolved significantly, driven by improved understanding
of the pathophysiology of chronic kidney disease (CKD) and the advent of novel treatment …
of the pathophysiology of chronic kidney disease (CKD) and the advent of novel treatment …
[PDF][PDF] Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
Diabetes mellitus is a multifactorial disorder of hyperglycemia caused by a combination of
biochemical, molecular and genetic factors, which leads to the dysfunction of various organs …
biochemical, molecular and genetic factors, which leads to the dysfunction of various organs …
Treatment of IgA nephropathy: evolution over half a century
Fifty years into the original description of IgA nephropathy, there is still no specific therapy for
this condition and general measures including blood pressure control with blockers of the …
this condition and general measures including blood pressure control with blockers of the …
The clinical course of IgA nephropathy after kidney transplantation and its management
S Lionaki, K Panagiotellis, C Melexopoulou… - Transplantation …, 2017 - Elsevier
Immunoglobulin (Ig) A nephropathy is one of the most common primary
glomerulonephritides worldwide causing end stage renal disease in up to 20–40% of …
glomerulonephritides worldwide causing end stage renal disease in up to 20–40% of …
Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis
M Simeoni, R Nicotera, M Colao, ML Citraro… - … urology and nephrology, 2016 - Springer
Non-diabetic glomerulonephritis is a frequent cause of end-stage renal disease. The use of
renin–angiotensin–aldosterone system blockers is a fundamental therapeutic approach …
renin–angiotensin–aldosterone system blockers is a fundamental therapeutic approach …